# Quaker BioVentures

> Quaker BioVentures is a VC fund backing Health Care and Biotechnology. See 38 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Philadelphia, United States
- Total investments: 38
- Last investment: Mar 2019
- Lead investor: 32%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/quaker-partners/about/
- Website: http://www.quakerbio.com

Quaker BioVentures is a venture capital firm investing in life science companies. The firm leads investments across the spectrum of the life science industry, including biopharmaceuticals, medical devices, human diagnostics, specialty pharmaceuticals, and healthcare services. Quaker BioVentures invests in companies at all stages of development,from early stage start-ups to public companies. Founded in 2003, the firm is currently investing Quaker BioVentures II, a $420 million fund formed in 2007. Quaker BioVentures manages over $700 million in committed capital.

## Contacts

5 contacts available for Quaker BioVentures. Shizune tracks 5 team members at Quaker BioVentures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/quaker-bioventures?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 23 | 61% |
| Biotechnology | 23 | 61% |
| Pharmaceutical | 12 | 32% |
| Medical | 9 | 24% |
| Therapeutics | 7 | 18% |

22 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 7 | 18% |
| Series C | 7 | 18% |
| Series D | 7 | 18% |
| Series B | 5 | 13% |
| Funding Round | 3 | 8% |

9 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Brenda D. Gavin | Partner | 0 | — |
| Richard S. Kollender | Partner | 1 | — |
| Adele C. Oliva | Partner | 3 | — |
| Geeta Vemuri | Partner | 13 | — |
| Ira Lubert | Founding Partner | 5 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Kaarta | Kaarta is the innovator of real-time mobile 3D reality capture, mapping complex environments with unprecedented speed, fidelity, and ease. It works without external signal infrastructures such as GPS or Wi-Fi. Kaarta’s patent-pending technology, rooted in advanced robotics, accurately transforms the real world into multi-dimensional 3D digitalmodels, streamlining workflow, reducing time, lowering cost, and providing a new level of understanding of spaces for humans and autonomous machines alike. The company was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania. | $6.5M | Series A | Mar 20, 2019 |  |
| PreCision Dermatology | PreCision Dermatology is a fully-integrated dermatology company with a mission to deliver innovative therapies to doctors and patients that demonstrably improve the care of skin. PreCision Dermatology is expanding rapidly through internally generated innovation, acquisitions, in-licensing, and co-marketing opportunities. | $67M | Debt Financing | Sep 23, 2013 |  |
| RainDance Technologies | RainDance Technologies is making complex genetics simple. The company’s ultra-sensitive genomic tools enable better research of novel non-invasive Fluid Biopsy™ applications that should result in more accurate, reliable, cost-effective and early detection of cancer, inherited and infectious diseases. Major research institutions and laboratoriesaround the world rely on RainDance systems’ performance. Based in Billerica, Massachusetts, the company supports customers using RainDrop Digital PCR and ThunderStorm Targeted Next-Generation Sequencing Systems through its international sales and service operations as well as a global network of distributors and commercial service providers. | $20.3M | Series E | Apr 29, 2013 |  |
| Intact Vascular | Intact Vascular is a privately held medical device company that develops minimally invasive peripheral vascular products. The Tack-It Endovascular System is designed to optimize peripheral balloon angioplasty results in the treatment of peripheral artery disease. This technology will offer physicians a new treatment option for treating peripheralartery disease. Intact Vascular is committed to developing safe and efficacious products for patients and for the physicians who use these products.The company was founded in 2011 and is located at Wayne, PA, USA. | $15.5M | Series A | Sep 05, 2012 |  |
| Tarsa Therapeutics | Tarsa Therapeutics is developing an oral formulation of calcitonin, a peptide hormone for the treatment of osteoporosis that slows the rate of bone destruction. | $28M | Series B | Mar 16, 2012 |  |
| Neuronetics | Neuronetics is focused on developing non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses. They are the first and only company to have a non-systemic and non-invasive depression treatment cleared by the FDA for patients who have not benefited from prior antidepressant treatment. |  | Series E | May 16, 2011 |  |
| RainDance Technologies | RainDance Technologies is making complex genetics simple. The company’s ultra-sensitive genomic tools enable better research of novel non-invasive Fluid Biopsy™ applications that should result in more accurate, reliable, cost-effective and early detection of cancer, inherited and infectious diseases. Major research institutions and laboratoriesaround the world rely on RainDance systems’ performance. Based in Billerica, Massachusetts, the company supports customers using RainDrop Digital PCR and ThunderStorm Targeted Next-Generation Sequencing Systems through its international sales and service operations as well as a global network of distributors and commercial service providers. | $37.5M | Series D | Jan 25, 2011 |  |
| Achillion Pharmaceuticals | At Achillion, we are driven to transform the lives of patients and families affected by diseases of the complement system, an integral part of the innate immune system. Scientific and clinical evidence has implicated the complement system, and specifically the complement Alternative Pathway (AP), in numerous devastating diseases and conditions. Ourprincipal focus at Achillion is to advance our clinical-stage portfolio of orally administered factor D inhibitors into late-stage development and potential commercialization for patients with devastating disorders of the complement system. | $50.1M | Post-IPO Equity | Aug 18, 2010 |  |
| Helomics | Helomics® is a comprehensive personalized healthcare company, bringing the next generation of diagnostics to the oncology field. Helomics is dedicated to improving patient outcomes by providing a personalized comprehensive tumor profile utilizing a proprietary set of laboratory platforms that leverage both tissue-based live and fixed cellular basedanalysis allowing physicians to characterize malignant tumors on a personalized basis. Helomics’ novel molecular and cellular markers and bioinformatics services support treatment decisions by providing vital information based on the specific biological processes of each individual’s cancer. | $33M | Series D | Jun 11, 2010 |  |
| TearScience | Headquartered in Morrisville, North Carolina, TearScience has pioneered devices that provide significant clinical identification and treatment of evaporative dry eye. Of the 100 million plus of dry eye sufferers worldwide, the leading cause (86percent) is evaporative dry eye, which is caused by Meibomian Gland Dysfunction (MGD) and a lipiddeficiency of the eye’s natural tear film. The Tear Film and Ocular Surface Society (TFOS) workshop, involving two years of work by 50 leading experts from around the world, concluded that MGD is an under-estimated condition and is very likely the most frequent cause of dry eye disease. Common symptoms of the disease include eye irritation, dryness, redness, tiredness, and visual disturbances. TearScience’s integrated, in-office system enables eye care professionals to effectively address a root cause of evaporative dry eye. |  | Series C | May 06, 2010 |  |

10 of 38 investments shown.

## Co-investors
- [Intersouth Partners](https://shizune.co/investors/profile/intersouth-partners) — VC Fund, 6 deals together
- [Johnson & Johnson Development Corporation](https://shizune.co/investors/profile/johnson-johnson-development-corporation) — VC Fund, 6 deals together
- [Birchmere Ventures](https://shizune.co/investors/profile/birchmere-ventures) — VC Fund, 5 deals together
- [Domain Associates](https://shizune.co/investors/profile/domain-associates) — VC Fund, 5 deals together
- [Adams Capital Management](https://shizune.co/investors/profile/adams-capital-management) — VC Fund, 4 deals together
- [Draper Triangle](https://shizune.co/investors/profile/draper-triangle-ventures) — VC Fund, 4 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Quaker BioVentures invest in?

Quaker BioVentures invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series A and Series C stage. Most of the 38 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Quaker BioVentures?

Public channels for Quaker BioVentures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Quaker BioVentures?

The team at Quaker BioVentures includes Brenda D. Gavin (Partner), Richard S. Kollender (Partner) and Adele C. Oliva (Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co